At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 30 enrolled
Drug / intervention
Invokana Pilldrug
Likely dose
Invokana Pill 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Efficacy and Tolerability of Canagliflozin in Healthy Individuals Comparing Dosing Protocols of Canagliflozin for Use as a Gerotherapeutic
In Brief
A Phase 4 clinical trial evaluating Invokana Pill for Healthy Aging. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The primary objective is to measure the effects that canagliflozin intervention has on reducing average glucose in healthy individuals. The secondary objective is to assess the tolerability and side effects and urinary glucose excretion following the pulsatile dosing protocol.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Aging
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20252026
Enrollment StartFeb 2024
First PostedMar 2024
Primary CompletionJun 2024
TodayJul 2026
First PostedMar 8, 2024
Enrollment StartFeb 12, 2024
Primary CompletionJun 29, 2024
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 2.3 years ago
Interventions
Invokana Pilldrug
100 mg and 150 mg doses, taken every day and every-other day, respectively.